Featured Research Search Results
Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2
Clinicaltrials.gov identifier:
NCT06177171
Treatment
Phase 1 treatment study for metastatic solid tumors
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations
Clinicaltrials.gov identifier:
NCT04890613
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT06401421
Treatment
Biomarker study for people with early-stage breast cancer
Study of the Drug Olvi-Vec in Women with Ovarian Cancer
Clinicaltrials.gov identifier:
NCT05281471
Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy
High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation
Clinicaltrials.gov identifier:
NCT05011383
Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04657068
Treatment
Phase 1/2 treatment study for advanced solid tumors
Sponsored By
